Samsung Biologics showcased its industry-leading contract development and manufacturing organization (CDMO) capabilities at Biologics Manufacturing Asia 2026 in Singapore, earning the prestigious Bioprocessing Excellence in Korea Award during the event.
The Korean CDMO leader highlighted its advanced CDO technologies and services at the conference on Wednesday. Lim Heon-chang, Director of Formulation Development at Samsung Biologics’ CDO division, presented compelling case studies of the company’s innovative high-concentration formulation development platform, S-Hicon.
Launched in 2024, S-Hicon supports the development of high-concentration biopharmaceuticals, which are gaining traction due to their potential to reduce patient dosing frequency and lower transportation and storage costs compared to lower-concentration alternatives.
Beyond S-Hicon, Samsung Biologics currently offers a comprehensive suite of nine CDO-related technical platforms. These include Developic, a platform assessing the feasibility of drug candidate development; S-CHOice, a proprietary, high-performance cell line platform; and S-CHOsient, a transient expression platform.
The Bioprocessing Excellence in Korea Award, presented during the Asia-Pacific Biopharma Excellence Awards 2026 on the sidelines of the conference, recognized Samsung Biologics’ robust process development capabilities and its global-standard manufacturing and quality systems. These systems provide comprehensive, end-to-end support for clients’ biopharmaceutical development needs.
The BMA, now in its 13th year, is one of Asia’s premier biopharmaceutical technology conferences. This year’s event, held Wednesday and Thursday, attracted approximately 1,200 participants and 500 companies.
hwkan
